Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of consumables (52.8%); - sale of equipment (28.8%); - provision of after-sales services (18.4%). The vast majority of net sales are earned abroad.

Employees

Sector

Advanced Medical Equipment & Technology

Calendar

10-14 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-10-01	€0.6840	-1.44%	15,424
26-09-30	€0.6940	-0.86%	26,494
26-09-29	€0.7000	-2.37%	54,037
26-09-28	€0.7170	-4.40%	42,625
26-09-25	€0.7500	+9.97%	241,869

Real-time Euronext Paris

More quotes

Annual profits - Rate of surprise

Company calendar

Real-time Euronext Paris 06:25:51 2026-10-01 EDT			5-day change	1st Jan Change
0.6840 ^EUR	-1.44%		+0.29%	+13.62%

09-16	Theraclion SA Reports Earnings Results for the Half Year Ended June 30, 2026	CI
09-16	Theraclion widens its operating loss in the first half

Market Cap	50.74M 57.62M 48.07M 43.4M 81.8M 5.52B 82.85M 575M 221M 2.82B 216M 212M 9.05B	P/E 2024	-2.66x	P/E 2025	-6.33x
Enterprise Value	58.59M 66.53M 55.51M 50.11M 94.45M 6.38B 95.67M 664M 256M 3.26B 250M 244M 10.46B	EV / Sales 2024	22.5x	EV / Sales 2025	55.4x
Free-Float	32.52%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Euronext Paris	ALTHE	Real-time
CBOE		Real-time
Boerse Muenchen	941	Real-time
Börse Stuttgart	941	Delayed
Deutsche Boerse AG	941	Delayed
CBOE		Real-time

09-16	Theraclion SA Reports Earnings Results for the Half Year Ended June 30, 2026	CI
09-16	Theraclion widens its operating loss in the first half
07-23	Theraclion SA Reports Consolidated Revenue Results for the First Half Ended June 30, 2026	CI
07-09	Theraclion Announces Board Changes	CI
07-09	Theraclion Appoints New Chairman	MT
06-19	Claude Lenoir appointed interim chairman of Theraclion
06-19	Theraclion Chairman Steps Down; Interim Successor Named	MT
06-18	Theraclion Announces Board Changes	CI
06-08	Theraclion Secures AMA CPT Editorial Panel Approval For New Category III CPT Code For Sonovein	CI
06-05	Theraclion deploys first Sonovein system in China
06-05	Theraclion JV Deploys Sonovein System at Chinese Hospital	MT
06-04	Theraclion Announces First Clinical Deployment Of Sonovein In Hainan, China	CI
06-04	Theraclion Deploys Sonovein System At Boao Super Hospital in Hainan Province	CI

Theraclion Stock

Stocks

ALTHE

FR0010120402

Advanced Medical Equipment & Technology

Valuation: Theraclion

Chart: Theraclion

Latest news: Theraclion

Press Releases: Theraclion

News in other languages: Theraclion

Quotes and Performance

Price Extremes

Managers and Directors: Theraclion

Latest insider transactions

Other Advanced Medical Equipment & Technology

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

09-16	2026 Half-Year Results: Theraclion Prepares for a New Stage in Its Development	BU
07-23	Theraclion Initiates Its Commercial Momentum in the First Half of 2026	BU
07-15	Theraclion: First Half 2026 Report on the Liquidity Contract With CRÉDIT INDUSTRIEL ET COMMERCIAL	BU
07-09	Theraclion Strengthens Its Governance by Appointing Vincent Gardès as Chairman of Its Board of Directors	BU
06-18	Theraclion Announces the Evolution of Its Board of Directors	BU

09-16	Theraclion creuse sa perte d'exploitation au 1er semestre
09-16	RÉSULTATS SEMESTRIELS 2026 : THERACLION SE PRÉPARE À UNE NOUVELLE ÉTAPE DE SON DÉVELOPPEMENT
07-23	THERACLION AMORCE SA DYNAMIQUE COMMERCIALE AU PREMIER SEMESTRE 2026
07-15	Theraclion: BILAN DU PREMIER SEMESTRE 2026 DU CONTRAT DE LIQUIDITÉ CONTRACTÉ AVEC LE CRÉDIT INDUSTRIEL ET COMMERCIAL
07-09	Vincent Gardès prend la présidence du conseil d'administration de Theraclion

1 day	-1.44%
1 week	+0.29%
Current month	-1.44%
1 month	-11.17%
3 months	+1.63%
6 months	+55.45%
Current year	+13.62%

1 week	0.67	0.76
1 month	0.63	0.76
Current year	0.4	0.93
1 year	0.4	0.93
3 years	0.14	1.25
5 years	0.14	1.9
10 years	0.14	6.3

Manager	Title	Age	Since
Martin Deterre CEO	Chief Executive Officer	-	2023-05-23
Julie Veisseire DFI	Director of Finance/CFO	-	-
Alexandra Rocher COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Mehdi El Glaoui BRD	Director/Board Member	-	2021-06-21
Cédric Bellanger BRD	Director/Board Member	-	2022-01-27
Lijuan Deng BRD	Director/Board Member	-	2023-06-28

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THERACLION	-1.44%	+0.29%	-7.57%	+20.00%	57.62M
THERMO FISHER SCIENTIFIC, INC.	-0.67%	+1.47%	+39.18%	+33.36%	250B
DANAHER CORPORATION	-2.02%	-0.00%	+11.75%	-10.70%	156B
INTUITIVE SURGICAL, INC.	-1.35%	+2.09%	-9.08%	+39.12%	144B
BOSTON SCIENTIFIC CORPORATION	-0.52%	-2.17%	-55.29%	-17.33%	63.26B
EDWARDS LIFESCIENCES CORPORATION	-2.00%	-0.58%	+10.99%	+24.60%	49.75B
AGILENT TECHNOLOGIES, INC.	-1.55%	+4.23%	+34.25%	+54.10%	48.58B
SIEMENS HEALTHINEERS AG	-1.04%	+1.05%	-18.79%	-21.78%	47.99B
VEEVA SYSTEMS INC.	+2.47%	+5.43%	-4.18%	+40.30%	46.22B
WATERS CORPORATION	-0.87%	+4.47%	+46.56%	+60.24%	43.17B
Average	-0.71%	+2.18%	+4.78%	+22.19%	84.8B
Weighted average by Cap.	-0.70%	+2.37%	+11.71%	+21.76%

	2024	2025
Net sales	830K 943K 787K 710K 1.34M 90.4M 1.36M 9.41M 3.62M 46.21M 3.54M 3.46M 148M	652K 740K 618K 558K 1.05M 70.99M 1.06M 7.39M 2.84M 36.29M 2.78M 2.72M 116M
Net income	-5.76M -6.54M -5.45M -4.92M -9.28M -627M -9.4M -65.26M -25.11M -320M -24.55M -24.01M -1.03B	-5.69M -6.46M -5.39M -4.87M -9.17M -620M -9.29M -64.5M -24.82M -317M -24.26M -23.73M -1.02B
Net Debt	3.41M 3.87M 3.23M 2.92M 5.5M 371M 5.57M 38.66M 14.88M 190M 14.54M 14.23M 609M	7.85M 8.92M 7.44M 6.72M 12.66M 855M 12.82M 89.01M 34.25M 437M 33.48M 32.75M 1.4B